Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Simvastatin
A A H Pharmaceuticals Ltd
C10AA01
Simvastatin
40mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02120000; GTIN: 5037563003082
PACKAGE LEAFLET: INFORMATION FOR THE USER SIMVADOR 10MG, 20MG, 40MG AND 80MG TABLETS Simvastatin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Simvador is and what it is used for 2. What you need to know before you take Simvador 3. How to take Simvador 4. Possible side effects 5. How to store Simvador 6. Contents of the pack and other information 1. WHAT SIMVADOR IS AND WHAT IT IS USED FOR Simvador is used to lower levels of total cholesterol, “bad” cholesterol (LDL cholesterol), and fatty substances called triglycerides in your blood. In addition, Simvador raises levels of “good” cholesterol (HDL cholesterol). While taking this medicine you should stick to a cholesterol-lowering diet. This medicine belongs to the class of drugs called statins. Simvador is used along with dieting if you have: · A raised cholesterol level in your blood (primar y hypercholesterolaemia) or high fat levels in your blood (mixed hyperlipidaemia) when exercise and weight loss have not worked. · A hereditar y illness called homozygous familial hypercholesterolaemia which causes the cholesterol levels in your blood to rise. You may get other medicines as well for this condition. · Coronary heart disease or are at high risk of suf fering from coronary heart disease. You are more likely to suffer from coronary heart disease if you have diabetes, have previously had a stroke, or have other blood vessel disease). Simvador may prolong your life by reducing the risk of heart disease problems, regardless of the amo Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Simvastatin 40 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 40 mg of the active ingredient simvastatin. Excipient with known effect Lactose monohydrate (tablet core) 281.72_ _mg per film-coated tablet Polydextrose (tablet coat only) 3.84 mg per film-coated tablet (containing NMT 4% glucose and NMT 2% sorbitol (E420)) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Simvastatin 40 mg film-coated tablets are presented as pink coloured, oval shaped, film-coated tablets with “G” on one side and “SM40” on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hypercholesterolaemia Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Treatment of homozygous familial hypercholaesterolemia (HoFH) as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. Cardiovascular prevention Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage range is 5-80 mg/day of simvastatin given orally as a single dose in the evening. Adjustments of dosage, if required, should be made at intervals of not less than 4 weeks, to a maximum of 80 mg/day given as a single dose in the evening. The 80-mg dose is only recommended in patients with severe hypercholesterolaemia and at high risk for cardiovascular complications, who have not achieved their treatment goals on lower doses and when the benefits are expected to outweigh the potential risks (see sections 4.4 and 5.1) Read the complete document